MTOR and hepatocellular carcinoma: Moreover, two recent multicenter prospective trials (one performed in Europe (Geissler et al., 2016) and the other performed in Korea (Lee K. W. et al., 2020) that compared mTOR inhibitor-only and TAC-only regimens in terms of the recurrence of HCC showed conflicting results for recurrence-free survival and overall survival after LT.